AUTHORS
Tarun Pant, PhD, Raman Gulab Brajesh, PhD2, Deron W Jones, MS3, Simi LNU, BS4, Billy W Day, PhD5, Stephen Naylor, PhD6, Matea Juric, BS7, Jacek Zielonka, PhD8, Kirkwood A Pritchard Jr, PhD9
AFFILIATIONS
1 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
2 Swami Vivekanand Technical University, Durg, Chhattisgarh, India
3 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
4 Swami Vivekanand Technical University, Durg, Chhattisgarh, India
5 ReNeuroGen LLC, Milwaukee, Wisconsin, United States
6 ReNeuroGen LLC, Milwaukee, Wisconsin, United States
7 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
8 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
9 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
ABSTRACT
Introduction: Pulmonary complications, including acute chest syndrome (ACS), remain the leading cause of morbidity and mortality in patients with sickle cell disease (SCD). Growing evidence indicates that impairment of erythrocyte (red blood cell, RBC) rheology, oxidative stress, and sterile inflammation all contribute to pulmonary vascular injury in SCD; however, it is not yet known whether oxidant-generating and inflammatory enzymes preferentially associate with sickle RBCs to amplify these processes. Building on our previous studies demonstrating elevated plasma myeloperoxidase (MPO) in both patients with SCD and Townes sickle mice, we tested the hypothesis that preferential association of MPO with sickle RBCs drives RBC oxidative injury, hemorheologic dysfunction, and pulmonary inflammatory remodeling.
Methods: Townes AA (expressing normal human hemoglobin) and SS (expressing sickle human hemoglobin) mice were treated with vehicle (PBS) or the selective MPO inhibitor N-acetyl-lysyltyrosylcysteine amide (KYC) for three weeks. MPO association with RBCs was assessed by biolayer interferometry and immunoblotting of RBC ghost preparations. RBC oxidative injury, hemorheology, pulmonary vasocongestion, lung histopathology, and whole-lung transcriptomic profiling (Affymetrix GeneChip), and high-dimensional flow cytometric immunophenotyping were evaluated to define the relationship between MPO-associated RBC oxidative injury and pulmonary inflammatory remodeling.
Results: Binding of immobilized MPO to sickle RBCs was significantly higher than to AA RBCs (15 min, p<0.05, n=3), with an estimated 3-fold higher binding rate. Complementary immunoblotting showed a greater amount of MPO bound to sickle RBC ghost preparations and an increased level of MPO-dependent oxidative modification products (chlorotyrosine and nitrotyrosine), identifying preferential MPO association as a previously unrecognized feature of sickle RBCs. In an independent cohort (n=5-6/group), systemic oxidative injury, as measured by plasma advanced oxidation protein products, was also significantly greater in SS mice (77% increase relative to AA+PBS controls, p<0.05), accompanied by a systemic increase in RBC sickling (p<0.05). In addition, QuPath analysis of hematoxylin and eosin-stained lung sections revealed a 10.3-fold increase in alveolar RBC burden in SS+PBS mice compared with AA+PBS, providing independent evidence of pulmonary RBC entrapment and vasocongestion. Consistent with these findings, SS lungs exhibited a 37% increase in mean linear intercept (MLI) and a 32% reduction in radial alveolar count (RAC), indicative of structural lung injury. These pulmonary changes were accompanied by a 46% reduction in circulating hematocrit and a 28% reduction in whole-blood viscosity in SS+PBS mice compared with AA+PBS, consistent with pulmonary sequestration of sickled RBCs. Pharmacologic inhibition of MPO with KYC significantly reduced plasma AOPP, RBC sickling, pulmonary RBC sequestration, structural lung injury (MLI/RAC), and restored hematocrit and whole-blood viscosity towards AA levels (all p<0.05). Independent confirmation of pulmonary vasocongestion and the coordinated activation of programs of innate immune responses, antigen processing, and pulmonary inflammatory remodeling was observed in SS lungs, and these programs were largely normalized upon MPO inhibition, as revealed by whole-lung transcriptomic profiling. These transcriptomic findings were subsequently confirmed by orthogonal approaches to histopathology, hematologic, and high-dimensional immunophenotyping, which further validated the underlying immune remodeling in the lungs at the cellular level.
Conclusion: Collectively, these data identify a new inflammatory phenotype of MPO-associated sickle RBCs, which is linked to both RBC oxidative injury and hemorheologic dysfunction, and thus to pulmonary vasocongestion and the inflammatory remodeling of the lung tissue. The data support the use of MPO inhibition as a potential translational approach to chronic complications associated with SCD.
DISCLOSURES
Tarun Pant, PhD: No relevant conflicts of interest to declare.